<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003008</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065583</org_study_id>
    <secondary_id>E1D95</secondary_id>
    <secondary_id>AMC-014</secondary_id>
    <nct_id>NCT00003008</nct_id>
  </id_info>
  <brief_title>Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Associated Malignancies Clinical Trials Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with&#xD;
      AIDS-related Kaposi's sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether the body distribution and plasma clearance of paclitaxel is affected&#xD;
           by protease inhibitors (e.g., indinavir, ritonavir, saquinavir mesylate, or nelfinavir&#xD;
           mesylate).&#xD;
&#xD;
      OUTLINE: Patients are stratified according to protease inhibitor treatment (yes vs no), prior&#xD;
      paclitaxel (yes vs no), and prior doxorubicin or daunorubicin (yes vs no).&#xD;
&#xD;
      Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 2 weeks for&#xD;
      at least 1 course in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      who previously received paclitaxel receive no more than 1 course during this study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saquinavir mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Kaposi's sarcoma requiring chemotherapy and/or currently&#xD;
             being treated with paclitaxel&#xD;
&#xD;
          -  Serologic diagnosis of HIV infection documented by a positive ELISA and confirmed with&#xD;
             a Western Blot or other federally approved HIV diagnostic test&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm ^3(with or without the use of&#xD;
             colony-stimulating factors)&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No greater than grade 2 peripheral neuropathy&#xD;
&#xD;
          -  No neuropsychiatric history or altered mental status that would preclude study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior or concurrent malignancy except curatively treated carcinoma in situ of&#xD;
             the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No sensitivity to E. coli-derived proteins&#xD;
&#xD;
          -  No active untreated infection&#xD;
&#xD;
          -  No new infectious complications requiring a change in antibiotics within the past 2&#xD;
             weeks&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 week since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to marker lesions&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior systemic treatment for Kaposi's sarcoma&#xD;
&#xD;
          -  At least 2 weeks since prior nonapproved FDA investigational agents except available&#xD;
             Investigational New Drugs that are antiretroviral agents&#xD;
&#xD;
          -  Concurrent maintenance therapy for opportunistic infections allowed&#xD;
&#xD;
          -  Concurrent commercially available antiretroviral therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Hayden Von Roenn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2003</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Group Chair</name_title>
    <organization>Eastern Cooperative Oncology Group</organization>
  </responsible_party>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

